Immunotherapy engagement in pancreatic adenocarcinoma: Provisional results of iLSTA study- Durvalumab, LSTA1 (certepetide), gemcitabine, and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma.

被引：0
|
作者：
Dean, Andrew Peter
Johansson, Mikael
Yusoff, Ian
Rao, Samarth
Sparrow, Susan
Kumarasinghe, Priyanthi
Navadgi, Suresh
Watanabe, Yuki
Webber, Laurence
Grew, Jenny
Fitzgerald, Shane
Comito, Olivia Rose
机构：
[1] St John God Subiaco Hosp, Subiaco, Australia
[2] Dept Upper GI Surg, Nedlands, Australia
[3] Sir Charles Gairdner Hosp, Nedlands, Australia
[4] Australian Clin Labs, Subiaco, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.746
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] FOLFIRINOX and gemcitabine/nab-paclitaxel efficacy in the treatment of locally advanced unresectable pancreatic adenocarcinoma.
    Bednar, Filip
    Ocuin, Lee Mayer
    Steve, Jennifer
    Zenati, Mazen S.
    Winters, Sharon
    Hogg, Melissa Ellen
    Bahary, Nathan
    Zeh, Herbert J.
    Zureikat, Amer H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [2] First line gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma.
    Gulhati, Pat
    Prakash, Laura
    Katz, Matthew H. G.
    Wang, Xuemei
    Javle, Milind M.
    Shroff, Rachna T.
    Fogelman, David R.
    Lee, Jeffrey Edwin
    Tzeng, Ching-Wei David
    Lee, Jeffrey H.
    Weston, Brian
    Tamm, Eric P.
    Bhosale, Priya
    Koay, Eugene Jon
    Maitra, Anirban
    Wang, Huamin
    Wolff, Robert A.
    Varadhachary, Gauri R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [3] A phase I study of gemcitabine/nab-paclitaxel/S-1 chemotherapy in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
    Chang, Chen
    Li, Xiaofen
    Cheng, Ke
    Cai, Zhaolun
    Xiong, Junjie
    Lv, Wanrui
    Li, Ruizhen
    Zhang, Pei
    Cao, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16261 - E16261
  • [4] ASCEND: A randomised, double-blinded, phase II study of gemcitabine and nab-paclitaxel with CEND-1/LSTA1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma.
    Dean, Andrew Peter
    Price, Timothy Jay
    Sjoquist, Katrin Marie
    Gebski, Val
    Mumford, Jan
    Day, Fiona
    Yip, Sonia
    Bradshaw, Nathan
    Jackson, Christopher G. C. A.
    Padinharakam, Shamsudheen
    Lee, Belinda
    Burge, Matthew E.
    Tebbutt, Niall C.
    Steer, Christopher B.
    Lomma, Chris
    Lam, Lyn
    Lee, Joanna
    Chantrill, Lorraine A.
    Harris, Marion
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
    Rogers, Jane E.
    Mizrahi, Jonathan D.
    Xiao, Lianchun
    Mohindroo, Chirayu
    Shroff, Rachna T.
    Wolff, Robert
    Varadhachary, Gauri R.
    Javle, Milind M.
    Overman, Michael
    Fogelman, David R.
    Raghav, Kanwal P. S.
    Pant, Shubham
    McAllister, Florencia
    CANCER MEDICINE, 2020, 9 (15): : 5406 - 5415
  • [6] Effectiveness and safety of nab-paclitaxel/gemcitabine in locally advanced or metastatic pancreatic adenocarcinoma
    Nebot-Villacampa, Maria-Jose
    Zafra-Morales, Ricardo
    Alfaro-Olea, Ascension
    Marin-Gorricho, Raquel
    Casajus-Navasal, Andrea
    Uriarte-Pinto, Moises
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (03) : 603 - 611
  • [7] Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarcinoma
    Pignon, Flore
    Turpin, Anthony
    Hentic, Olivia
    Coriat, Romain
    Salmon, Emma
    Baumgaertner, Isabelle
    Bertrand, Nicolas
    Levy, Philippe
    Rebours, Vinciane
    Hammel, Pascal
    de Mestier, Louis
    PANCREATOLOGY, 2021, 21 (06) : 1064 - 1070
  • [8] A study of relacorilant in combination with nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.
    Borazanci, Erkut Hasan
    Bahary, Nathan
    Oberstein, Paul Eliezer
    Chung, Vincent
    Skeel, Roland T.
    Chiorean, E. Gabriela
    Greenstein, Andrew E.
    Pashova, Hristina I.
    Tudor, Iulia Cristina
    Mann, Grace
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
    Shuling Chen
    Jiaxin Li
    Aoran Dong
    Zelong Liu
    Meiyan Zhu
    Meng Jin
    Guangyan Wei
    Shuang Wu
    Yan Wang
    Yong Chen
    Zhenwei Peng
    Journal of Hematology & Oncology, 16
  • [10] Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
    Chen, Shuling
    Li, Jiaxin
    Dong, Aoran
    Liu, Zelong
    Zhu, Meiyan
    Jin, Meng
    Wei, Guangyan
    Wu, Shuang
    Wang, Yan
    Chen, Yong
    Peng, Zhenwei
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
12345